These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 35284989)

  • 21. Evaluation of machine learning-based classification of clinical impairment and prediction of clinical worsening in multiple sclerosis.
    Noteboom S; Seiler M; Chien C; Rane RP; Barkhof F; Strijbis EMM; Paul F; Schoonheim MM; Ritter K
    J Neurol; 2024 Aug; 271(8):5577-5589. PubMed ID: 38909341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spatial distribution of multiple sclerosis lesions in the cervical spinal cord.
    Eden D; Gros C; Badji A; Dupont SM; De Leener B; Maranzano J; Zhuoquiong R; Liu Y; Granberg T; Ouellette R; Stawiarz L; Hillert J; Talbott J; Bannier E; Kerbrat A; Edan G; Labauge P; Callot V; Pelletier J; Audoin B; Rasoanandrianina H; Brisset JC; Valsasina P; Rocca MA; Filippi M; Bakshi R; Tauhid S; Prados F; Yiannakas M; Kearney H; Ciccarelli O; Smith SA; Andrada Treaba C; Mainero C; Lefeuvre J; Reich DS; Nair G; Shepherd TM; Charlson E; Tachibana Y; Hori M; Kamiya K; Chougar L; Narayanan S; Cohen-Adad J
    Brain; 2019 Mar; 142(3):633-646. PubMed ID: 30715195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.
    Zivadinov R; Sepcic J; Nasuelli D; De Masi R; Bragadin LM; Tommasi MA; Zambito-Marsala S; Moretti R; Bratina A; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M
    J Neurol Neurosurg Psychiatry; 2001 Jun; 70(6):773-80. PubMed ID: 11385012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deep learning of joint myelin and T1w MRI features in normal-appearing brain tissue to distinguish between multiple sclerosis patients and healthy controls.
    Yoo Y; Tang LYW; Brosch T; Li DKB; Kolind S; Vavasour I; Rauscher A; MacKay AL; Traboulsee A; Tam RC
    Neuroimage Clin; 2018; 17():169-178. PubMed ID: 29071211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of brain magnetic resonance imaging lesions in multiple sclerosis by race with reference to disability progression.
    Nakamura Y; Gaetano L; Matsushita T; Anna A; Sprenger T; Radue EW; Wuerfel J; Bauer L; Amann M; Shinoda K; Isobe N; Yamasaki R; Saida T; Kappos L; Kira JI
    J Neuroinflammation; 2018 Sep; 15(1):255. PubMed ID: 30185189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI.
    Dal-Bianco A; Grabner G; Kronnerwetter C; Weber M; Kornek B; Kasprian G; Berger T; Leutmezer F; Rommer PS; Trattnig S; Lassmann H; Hametner S
    Brain; 2021 Apr; 144(3):833-847. PubMed ID: 33484118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimated connectivity networks outperform observed connectivity networks when classifying people with multiple sclerosis into disability groups.
    Tozlu C; Jamison K; Gu Z; Gauthier SA; Kuceyeski A
    Neuroimage Clin; 2021; 32():102827. PubMed ID: 34601310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Global and Regional Deep Learning Models for Multiple Sclerosis Stratification From MRI.
    Coll L; Pareto D; Carbonell-Mirabent P; Cobo-Calvo Á; Arrambide G; Vidal-Jordana Á; Comabella M; Castilló J; Rodrı Guez-Acevedo B; Zabalza A; Galán I; Midaglia L; Nos C; Auger C; Alberich M; Río J; Sastre-Garriga J; Oliver A; Montalban X; Rovira À; Tintoré M; Lladó X; Tur C
    J Magn Reson Imaging; 2024 Jul; 60(1):258-267. PubMed ID: 37803817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of T2 lesion-based disease activity volume outcomes in predicting disease progression in multiple sclerosis over 10 years.
    Oship D; Jakimovski D; Bergsland N; Horakova D; Uher T; Vaneckova M; Havrdova E; Dwyer MG; Zivadinov R
    Mult Scler Relat Disord; 2022 Nov; 67():104187. PubMed ID: 36150263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis.
    Hofstetter L; Naegelin Y; Filli L; Kuster P; Traud S; Smieskova R; Mueller-Lenke N; Kappos L; Gass A; Sprenger T; Penner IK; Nichols TE; Vrenken H; Barkhof F; Polman C; Radue EW; Borgwardt SJ; Bendfeldt K
    Mult Scler; 2014 Feb; 20(2):202-13. PubMed ID: 23804554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
    Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R
    J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines.
    Chu R; Kim G; Tauhid S; Khalid F; Healy BC; Bakshi R
    PLoS One; 2018; 13(11):e0206939. PubMed ID: 30408094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Positron Emission Tomography with [
    Hamzaoui M; Garcia J; Boffa G; Lazzarotto A; Absinta M; Ricigliano VAG; Soulier T; Tonietto M; Gervais P; Bissery A; Louapre C; Bottlaender M; Bodini B; Stankoff B
    Ann Neurol; 2023 Aug; 94(2):366-383. PubMed ID: 37039158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS.
    Xiang B; Brier MR; Kanthamneni M; Wen J; Snyder AZ; Yablonskiy DA; Cross AH
    Mult Scler; 2022 Sep; 28(10):1515-1525. PubMed ID: 35196933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retinal nerve fiber and ganglion cell complex layer thicknesses mirror brain atrophy in patients with relapsing-remitting multiple sclerosis.
    Glasner P; Sabisz A; Chylińska M; Komendziński J; Wyszomirski A; Karaszewski B
    Restor Neurol Neurosci; 2022; 40(1):35-42. PubMed ID: 35180139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deciphering multiple sclerosis disability with deep learning attention maps on clinical MRI.
    Coll L; Pareto D; Carbonell-Mirabent P; Cobo-Calvo Á; Arrambide G; Vidal-Jordana Á; Comabella M; Castilló J; Rodríguez-Acevedo B; Zabalza A; Galán I; Midaglia L; Nos C; Salerno A; Auger C; Alberich M; Río J; Sastre-Garriga J; Oliver A; Montalban X; Rovira À; Tintoré M; Lladó X; Tur C
    Neuroimage Clin; 2023; 38():103376. PubMed ID: 36940621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of deep grey matter volume on cognition in multiple sclerosis.
    Lorefice L; Carta E; Frau J; Contu F; Casaglia E; Coghe G; Barracciu MA; Cocco E; Fenu G
    Mult Scler Relat Disord; 2020 Oct; 45():102351. PubMed ID: 32731200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early-stage volume losses in the corpus callosum and thalamus predict the progression of brain atrophy in patients with multiple sclerosis.
    Fujimori J; Nakashima I
    J Neuroimmunol; 2024 Feb; 387():578280. PubMed ID: 38171046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gray matter atrophy is related to long-term disability in multiple sclerosis.
    Fisniku LK; Chard DT; Jackson JS; Anderson VM; Altmann DR; Miszkiel KA; Thompson AJ; Miller DH
    Ann Neurol; 2008 Sep; 64(3):247-54. PubMed ID: 18570297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis.
    Buchmann A; Pirpamer L; Pinter D; Voortman M; Helmlinger B; Pichler A; Maceski AM; Benkert P; Bachmaier G; Ropele S; Reindl M; Leppert D; Kuhle J; Enzinger C; Khalil M
    Eur J Neurol; 2023 May; 30(5):1389-1399. PubMed ID: 36779855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.